The United States has granted approval for a novel COVID-19 vaccine developed by Moderna, albeit with certain limitations regarding its governance. This new vaccine is not intended to replace Moderna’s existing vaccine but rather to serve as an additional option for specific groups.

Known as mNexspike, this next-generation coronavirus vaccine utilizes a refined approach, allowing for a lower dosage-specifically, one-fifth of the dose found in Moderna’s current COVID-19 vaccine, Spikevax-by concentrating on a more precise immune target.

According to Stephane Bancel, Moderna’s CEO, the approval “adds an important new tool to help protect people at high risk of severe disease from COVID-19.”

The Food and Drug Administration has authorized the use of the new vaccine for adults aged 65 and older, as well as individuals between 12 and 64 years of age who have at least one underlying health condition that elevates their risk of severe illness from the coronavirus.

This restriction mirrors the limitations imposed by the FDA when licensing another COVID-19 vaccine from Novavax.

these limitations mark a shift from previous U.S. COVID-19 vaccine policies, potentially reflecting concerns about vaccines from figures such as Health Secretary Robert F. kennedy Jr..

Moderna’s existing vaccine, which does not have these limitations, has been available for individuals aged 6 months and older. The company anticipates offering both vaccine options this fall.

The FDA’s approval was based on a study of 11,400 people age 12 and older that compared the new low-dose vaccine with Moderna’s existing vaccine. The study indicated that the new vaccine was safe and at least as effective as the original shot.

This announcement follows the Trump administration’s decision to discontinue funding for Moderna’s research into a vaccine for potential pandemic flu viruses, including the H5N1 bird flu, despite encouraging preliminary study results.